BEHRENS M KATHLEEN 4
4 · IGM Biosciences, Inc. · Filed Aug 14, 2025
Insider Transaction Report
Form 4
BEHRENS M KATHLEEN
Director
Transactions
- Disposition to Issuer
Common Stock
2025-08-14−22,222→ 0 total - Disposition to Issuer
Common Stock
2025-08-14−330,700→ 0 total(indirect: See footnote) - Disposition to Issuer
Common Stock
2025-08-14−29,807→ 0 total(indirect: See footnote) - Disposition to Issuer
Common Stock
2025-08-14−29,806→ 0 total(indirect: See footnote)
Footnotes (4)
- [F1]Pursuant to the Agreement and Plan of Merger dated July 1, 2025, by and among IGM Biosciences, Inc. (the "Company"), Concentra Biosciences, LLC, a Delaware limited liability company ("Parent"), and Concentra Merger Sub V, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), on August 14, 2025, Merger Sub merged with and into the Company (the "Merger"), with the Company continuing as the surviving corporation and a wholly owned subsidiary of Parent. In connection with the Merger, each issued and outstanding share of the Company's Common Stock was cancelled and converted into the right to receive (i) an amount equal to $1.247 in cash and (ii) one contractual contingent value right (a "CVR") subject to the terms and conditions of a Contingent Value Rights Agreement.
- [F2]Prior to the Merger, the shares were held in the name of KBW 2005 Trust for which Reporting Person is the Trustee.
- [F3]Prior to the Merger, the shares were held in the name of Non-Exempt Trust for Patrick R. Wilsey Under the Alfred S. Wilsey, Jr. Revocable Trust for which Reporting Person is a Trustee.
- [F4]Prior to the Merger, the shares were held in the name of Non-Exempt Trust for Shannon K. Wilsey Under the Alfred S. Wilsey, Jr. Revocable Trust for which Reporting Person is a Trustee.